Delenex Therapeutics Extends Scientific Advisory Board
Renowned Key Opinion Leaders to Support Development of Delenex’ Oncology Pipeline
Schlieren/Zurich, July 6, 2015 – Delenex Therapeutics AG, a clinical stage antibody company developing treatments for oncological and dermatological diseases using its proprietary and validated PENTRA®Body platform, today announced the extension of its scientific advisory board. Two world-renowned oncology specialists will bring strong clinical, scientific and drug formulation expertise to assist Delenex in developing and implementing its corporate and R&D strategy.
The new members of the advisory board are:
Roger Stupp, M.D., Professor and Chairman of the Department of Oncology at the University of Zurich, Switzerland. He also serves as the President of the European Organisation for Research and Treatment of Cancer (EORTC). Prof. Stupp is known for his practice-changing novel strategies in the field of neuro-oncology, and has made significant contributions to clinical research and the launch of novel chemotherapeutics, and Michael Weller, M.D., Professor and Chairman of the Department of Neurology, University of Zurich, Switzerland. He serves as President of the European Association of Neuro-Oncology (EANO) and as Chairman of the Brain Tumor Group of the EORTC. Prof. Weller is an internationally renowned researcher in brain tumors and has extensive experience in the diagnosis and therapy of glioblastoma and other primary brain tumors. He is involved in many clinical protocols and is instrumental in the development of novel therapies for this highly aggressive cancer.
“We are delighted and honored to have these internationally acknowledged leaders in oncology join our advisory board,” said Thomas Hecht, Delenex’ Executive Chairman. “Their expertise will be key in advancing our therapeutic programs.”
About Delenex Therapeutics AG
Delenex is a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from a variety of oncological and dermatological diseases. Delenex’ proprietary PENTRA®Bodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body. The modular PENTRA®Body platform has proven ability to identify and rapidly generate best-in-class antibodies of various formats including single chain Fv fragments (scFv), IgG and bispecific antibodies. Delenex’ validated humanized scFv have applications in immunotherapy in improving CAR-T cells and as TCR-like antibodies.
Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company).
Help employers find you! Check out all the jobs and post your resume.
Schlieren/Zurich, July 6, 2015 – Delenex Therapeutics AG, a clinical stage antibody company developing treatments for oncological and dermatological diseases using its proprietary and validated PENTRA®Body platform, today announced the extension of its scientific advisory board. Two world-renowned oncology specialists will bring strong clinical, scientific and drug formulation expertise to assist Delenex in developing and implementing its corporate and R&D strategy.
The new members of the advisory board are:
Roger Stupp, M.D., Professor and Chairman of the Department of Oncology at the University of Zurich, Switzerland. He also serves as the President of the European Organisation for Research and Treatment of Cancer (EORTC). Prof. Stupp is known for his practice-changing novel strategies in the field of neuro-oncology, and has made significant contributions to clinical research and the launch of novel chemotherapeutics, and Michael Weller, M.D., Professor and Chairman of the Department of Neurology, University of Zurich, Switzerland. He serves as President of the European Association of Neuro-Oncology (EANO) and as Chairman of the Brain Tumor Group of the EORTC. Prof. Weller is an internationally renowned researcher in brain tumors and has extensive experience in the diagnosis and therapy of glioblastoma and other primary brain tumors. He is involved in many clinical protocols and is instrumental in the development of novel therapies for this highly aggressive cancer.
“We are delighted and honored to have these internationally acknowledged leaders in oncology join our advisory board,” said Thomas Hecht, Delenex’ Executive Chairman. “Their expertise will be key in advancing our therapeutic programs.”
About Delenex Therapeutics AG
Delenex is a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from a variety of oncological and dermatological diseases. Delenex’ proprietary PENTRA®Bodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body. The modular PENTRA®Body platform has proven ability to identify and rapidly generate best-in-class antibodies of various formats including single chain Fv fragments (scFv), IgG and bispecific antibodies. Delenex’ validated humanized scFv have applications in immunotherapy in improving CAR-T cells and as TCR-like antibodies.
Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company).
Help employers find you! Check out all the jobs and post your resume.